In 2005, in a companion study conducted on tumor specimens from patients enrolled in the EORTC_26981/NCIC_CE.3 (Stupp et al., 2005b), Hegi et al. (2005) demonstrated a pronounced favorable response in patients whose tumors had lost MGMT activity via promoter methylation. The gene discussed is MGMT; the disease is neoplasm.